Structural variation in the glycogen synthase kinase 3β and brain‐derived neurotrophic factor genes in Japanese patients with bipolar disorders

Abstract Background Lithium is the first‐line drug for the treatment of bipolar disorders (BDs); however, not all patients responded. Glycogen synthase kinase (GSK) 3β and brain‐derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium. Since structural variations were repo...

詳細記述

書誌詳細

主要な著者:	Yosuke Suga, Keiichiro Yoshimoto, Shusuke Numata, Shinji Shimodera, Shogo Takamura, Naoto Kamimura, Ken Sawada, Hiromitsu Kazui, Tetsuro Ohmori, Shigeru Morinobu
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2020-03-01
シリーズ:	Neuropsychopharmacology Reports
主題:	bipolar disorder brain‐derived neurotrophic factor copy number variation glycogen synthase kinase 3® lithium
オンライン･アクセス:	https://doi.org/10.1002/npr2.12083
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!